Diabetic ketoacidosis (DKA) is a serious complication of type 1 diabetes mellitus, accounting for around 6% of cases. It can also occur in rare cases of extreme stress in patients with type 2 diabetes mellitus. However, mortality rates have decreased from 8% to under 1% in the past 20 years. DKA is caused by uncontrolled lipolysis, resulting in an excess of free fatty acids that are ultimately converted to ketone bodies. The most common precipitating factors of DKA are infection, missed insulin doses, and myocardial infarction. Symptoms include abdominal pain, polyuria, polydipsia, dehydration, Kussmaul respiration, and acetone-smelling breath. Diagnostic criteria include glucose levels above 13.8 mmol/l, pH below 7.30, serum bicarbonate below 18 mmol/l, anion gap above 10, and ketonaemia.

Management of DKA involves fluid replacement, insulin, and correction of electrolyte disturbance. Most patients with DKA are depleted around 5-8 litres, and isotonic saline is used initially, even if the patient is severely acidotic. Insulin is administered through an intravenous infusion, and correction of electrolyte disturbance is necessary. Long-acting insulin should be continued, while short-acting insulin should be stopped. DKA resolution is defined as pH above 7.3, blood ketones below 0.6 mmol/L, and bicarbonate above 15.0mmol/L. Complications may occur from DKA itself or the treatment, such as gastric stasis, thromboembolism, arrhythmias, acute respiratory distress syndrome, acute kidney injury, and cerebral oedema. Children and young adults are particularly vulnerable to cerebral oedema following fluid resuscitation in DKA and often need 1:1 nursing to monitor neuro-observations.

While acanthosis nigricans may occur on its own in individuals with dark skin, it is typically a sign of insulin resistance and associated conditions such as type 2 diabetes, polycystic ovarian syndrome, Cushing’s syndrome, and hypothyroidism. Certain medications, including corticosteroids, insulin, and hormone medications, can also cause this condition. If acanthosis nigricans appears suddenly and in unusual areas such as the mouth, it may indicate the presence of an internal malignancy, particularly gastric cancer.

Acanthosis nigricans is a condition characterized by the presence of symmetrical, brown, velvety plaques on the neck, axilla, and groin. This condition can be caused by various factors such as type 2 diabetes mellitus, gastrointestinal cancer, obesity, polycystic ovarian syndrome, acromegaly, Cushing’s disease, hypothyroidism, familial factors, Prader-Willi syndrome, and certain drugs like the combined oral contraceptive pill and nicotinic acid. The pathophysiology of acanthosis nigricans involves insulin resistance, which leads to hyperinsulinemia. This, in turn, stimulates the proliferation of keratinocytes and dermal fibroblasts through interaction with insulin-like growth factor receptor-1 (IGFR1).

If methotrexate and trimethoprim-containing antibiotics are used together, it may lead to severe or fatal pancytopenia and bone marrow suppression. This patient, who takes methotrexate for rheumatoid arthritis, has presented with pancytopenia and feeling unwell. Myelosuppression is a known adverse effect of methotrexate, which can be exacerbated by renal impairment and certain medications.

Methotrexate: An Antimetabolite with Potentially Life-Threatening Side Effects

Methotrexate is an antimetabolite drug that inhibits the enzyme dihydrofolate reductase, which is essential for the synthesis of purines and pyrimidines. It is commonly used to treat inflammatory arthritis, psoriasis, and some types of leukemia. However, it is considered an important drug due to its potential for life-threatening side effects. Careful prescribing and close monitoring are essential to ensure patient safety.

The adverse effects of methotrexate include mucositis, myelosuppression, pneumonitis, pulmonary fibrosis, and liver fibrosis. The most common pulmonary manifestation is pneumonitis, which typically develops within a year of starting treatment and presents with non-productive cough, dyspnea, malaise, and fever. Women should avoid pregnancy for at least 6 months after treatment has stopped, and men using methotrexate need to use effective contraception for at least 6 months after treatment.

When prescribing methotrexate, it is important to follow guidelines and monitor patients regularly. Methotrexate is taken weekly, and FBC, U&E, and LFTs need to be regularly monitored. The starting dose is 7.5 mg weekly, and folic acid 5mg once weekly should be co-prescribed, taken more than 24 hours after the methotrexate dose. Only one strength of methotrexate tablet should be prescribed, usually 2.5 mg. It is also important to avoid prescribing trimethoprim or co-trimoxazole concurrently, as it increases the risk of marrow aplasia, and high-dose aspirin increases the risk of methotrexate toxicity.

In case of methotrexate toxicity, the treatment of choice is folinic acid. Methotrexate is a drug with a high potential for patient harm, and it is crucial to be familiar with guidelines relating to its use to ensure patient safety.

Stages of Diabetic Retinopathy

Diabetic retinopathy is a condition that affects the eyes of people with diabetes. It is important to detect and treat it early to prevent vision loss. There are different stages of diabetic retinopathy, each with its own set of features.

Grade 1 is characterized by arteriolar narrowing. Grade 2 includes features of grade 1 and arteriovenous nipping. Grade 3 includes features of grade 2 and microaneurysms, dot-and-blot haemorrhages, flame-shaped haemorrhages, cotton-wool spots, and hard exudates. Grade 4 includes features of grade 3 and optic disc swelling.

It is important to have regular eye exams if you have diabetes to detect any signs of diabetic retinopathy early. With proper management and treatment, vision loss can be prevented or delayed.

Types of Kidney Tumours and Their Characteristics

Kidney tumours can present with symptoms such as haematuria, loin pain, fatigue, and weight loss. These symptoms should be considered as red flags for urgent referral for potential renal cancer. Renal cell carcinomas are the most common type of kidney tumours in adults, accounting for 80% of renal cancers. They are divided into clear cell (most common), papillary, chromophobe, and collecting duct carcinomas. Sarcomatoid renal cancers are rare and have a poorer prognosis compared to other types of renal cancer. Angiomyolipomas are benign kidney tumours commonly seen in patients with tuberous sclerosis. Transitional cell carcinomas account for 5-10% of adult kidney tumours and start in the renal pelvis. They are the most common type of cancer in the ureters, bladder, and urethra. Wilms’ tumour is the most common kidney cancer in children and is not likely to be found in adults.

Understanding the Different Types of Kidney Tumours

Ulcerative colitis can be managed through inducing and maintaining remission. The severity of the condition is classified as mild, moderate, or severe based on the number of stools and presence of systemic upset. Treatment for mild-to-moderate cases of proctitis involves using topical aminosalicylate, while proctosigmoiditis and left-sided ulcerative colitis may require a combination of oral and topical medications. Extensive disease may require a high-dose oral aminosalicylate and topical treatment. Severe colitis should be treated in a hospital with intravenous steroids or ciclosporin. Maintaining remission can involve using a low maintenance dose of an oral aminosalicylate or oral azathioprine/mercaptopurine. Methotrexate is not recommended, but probiotics may prevent relapse in mild to moderate cases.

Thyroid Management During Pregnancy: Considerations and Recommendations

Pregnancy can have a significant impact on thyroid function, and thyroid dysfunction can occur in many pregnant women due to pathological processes. Anti-thyroid drugs such as propylthiouracil and carbimazole can cross the placenta, potentially causing fetal goitre and hypothyroidism. It is recommended to keep the dose of these drugs as low as possible to maintain euthyroidism during pregnancy. Neonatal goitre and hypothyroidism can occur even with low-dose anti-thyroid drugs, and the neonatal goitre is permanent if it occurs.

Block-and-replace therapy with carbimazole and thyroxine is appropriate maternal management only in the treatment of isolated fetal hyperthyroidism caused by maternal TSH receptor antibody production in a mother who previously received ablative therapy for Graves’ disease. The neonatal goitre and hypothyroidism normalise in a few days’ time, and the confirmatory tests will come back normal even if the TSH is high on screening.

Specialist assessment is needed to differentiate between Graves’ hyperthyroidism and gestational hyperthyroidism. Women treated with anti-thyroid drugs may need to have the drug or dose amended by a specialist at the diagnosis of pregnancy, because these drugs cross the placenta. Women with current or previous Graves’ disease should have their TSH receptor antibody levels measured by the specialist. Carbimazole and propylthiouracil are present in breast milk, but this does not preclude breastfeeding as long as neonatal development is closely monitored and the lowest effective dose is used.

In summary, thyroid management during pregnancy requires careful consideration and monitoring to ensure the health of both the mother and the fetus.

Physiological Changes in Cardiovascular System During Pregnancy

During pregnancy, the cardiovascular system undergoes significant changes to accommodate the growing fetus. These changes include a drop in diastolic blood pressure by 10 mmHg during the second trimester, circulating blood volume increases by approximately 50%, leading to a dilutional ‘physiological anaemia’ and cardiac output increases most sharply throughout the first trimester.

During pregnancy, heart rate progressively increases until reaching a peak in the third trimester. The overall change in heart rate represents approximately a 20–25% increase from baseline. However, a grade 2/6 diastolic murmur at the mitral area and pulsus alternans are not typical findings in a healthy pregnancy. It is important for healthcare providers to be aware of these physiological changes to properly monitor and manage the health of pregnant individuals.

Treatment and Diagnosis of Acute Pancreatitis

Acute pancreatitis can lead to systemic inflammatory response syndrome and multiple organ dysfunction syndromes. The mainstay of treatment is supportive measures such as fluid resuscitation and oxygen supplementation. Abdominal ultrasound can be useful to identify gallstones as the cause of pancreatitis, but fluid resuscitation takes priority. IV antibiotics are not indicated unless complications occur. Enteral feeding is preferred over nil by mouth, and parenteral feeding should be considered if enteral feeding is not tolerated. Urgent CT of the abdomen is not necessary in the acute stage unless complications are suspected. However, for severe pancreatitis, contrast-enhanced CT may be indicated four days after initial symptoms to assess for complications.

According to the 2016 guidelines of the British Thoracic Society, children should be given a specific dose of steroids based on their age. For children under 2 years, the dose should be 10 mg of prednisolone, for those aged 2-5 years, it should be 20 mg, and for those over 5 years, it should be 30-40 mg. Children who are already taking maintenance steroid tablets should receive a maximum dose of 60 mg or 2 mg/kg of prednisolone. If a child vomits after taking the medication, the dose should be repeated, and if they are unable to retain the medication orally, intravenous steroids should be considered. The duration of treatment should be tailored to the number of days required for recovery, and a course of steroids exceeding 14 days does not require tapering.

Managing Acute Asthma Attacks in Children

When it comes to managing acute asthma attacks in children, it is important to assess the severity of the attack and take appropriate action. For children between the ages of 2 and 5, those with severe or life-threatening asthma should be immediately transferred to the hospital. For moderate attacks, children should have a SpO2 level above 92% and no clinical features of severe asthma. However, for severe attacks, children may have a SpO2 level below 92%, be too breathless to talk or feed, have a heart rate above 140/min, and use accessory neck muscles. For life-threatening attacks, children may have a SpO2 level below 92%, a silent chest, poor respiratory effort, agitation, altered consciousness, and cyanosis.

For children over the age of 5, it is recommended to attempt to measure PEF in all cases. For moderate attacks, children should have a SpO2 level above 92%, a PEF level above 50% best or predicted, and no clinical features of severe asthma. For severe attacks, children may have a SpO2 level below 92%, a PEF level between 33-50% best or predicted, and be unable to complete sentences in one breath or too breathless to talk or feed. For life-threatening attacks, children may have a SpO2 level below 92%, a PEF level below 33% best or predicted, a silent chest, poor respiratory effort, altered consciousness, and cyanosis.

For children with mild to moderate acute asthma, bronchodilator therapy should be given via a beta-2 agonist and spacer (or close-fitting mask for children under 3 years old). One puff should be given every 30-60 seconds up to a maximum of 10 puffs. If symptoms are not controlled, the beta-2 agonist should be repeated and the child should be referred to the hospital. Steroid therapy should also be given to all children with an asthma exacerbation for 3-5 days, with the usual prednisolone dose varying based on age and weight.